ABI 2280
Alternative Names: ABI-2280Latest Information Update: 18 Jul 2024
At a glance
- Originator Antiva Biosciences
- Class Antineoplastics; Antivirals
- Mechanism of Action Apoptosis stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cervical intraepithelial neoplasia; Human papillomavirus infections
Most Recent Events
- 27 Mar 2024 Phase-I/II clinical trials in Human papillomavirus infections in Australia (Vaginal) (NCT06491446)
- 27 Nov 2023 Early research in Human papillomavirus infections in USA (Vaginal) (Antiva Biosciences pipeline, November 2023)
- 27 Nov 2023 Antiva Biosciences plans a phase II trial for Cervical intraepithelial neoplasia in early 2024 (Antiva Biosciences pipeline, November 2023)